Screening for Gestational Diabetes in Pregnant Women

Risk Assessment for Early GDM Screening

• Women with a BMI ≥30 kg/m² should be screened for gestational diabetes at their first prenatal visit (12-14 weeks) due to their significantly higher risk of GDM and associated maternal and fetal complications, as recommended by the American College of Physicians and endorsed by other guideline societies 1, 2
• A history of previous GDM is a significant risk factor for GDM, with a 4.14 times higher risk compared to women with normal BMI, according to the American College of Obstetricians and Gynecologists 1, 3
• Family history of diabetes in first-degree relatives is also a high-risk factor that warrants early screening, as stated by the American Diabetes Association 1, 3
• Belonging to high-risk ethnic groups (Hispanic, Native American, South or East Asian, African American, or Pacific Island descent) is another factor that increases the risk of GDM, according to the National Institute of Diabetes and Digestive and Kidney Diseases 1, 3

Screening Recommendations Based on BMI

• For women with BMI ≥30 kg/m², the American College of Obstetricians and Gynecologists recommends screening at first prenatal visit (12-14 weeks) and repeating screening at 24-28 weeks if initial screening is negative, with a strength of evidence rated as high 1, 2, 4
• For women with BMI 25-29.9 kg/m² with additional risk factors, the American College of Physicians suggests considering early screening at first prenatal visit and repeating screening at 24-28 weeks if initial screen is negative, with a moderate strength of evidence 1, 3, 4

Screening Methods

• The two-step approach, commonly used in the US, involves a 50g glucose challenge test (GCT) in non-fasting state, followed by a 100g oral glucose tolerance test (OGTT) if GCT ≥130-140 mg/dL, as recommended by the American Diabetes Association 1
• The one-step approach involves a 75g OGTT with evaluation of fasting, 1-hour, and 2-hour glucose levels, as endorsed by the International Diabetes Federation 2, 3

Clinical Considerations

• Not repeating screening at 24-28 weeks in high-risk women who initially test negative may lead to delayed diagnosis and treatment, according to the American College of Obstetricians and Gynecologists 1, 3
• Overlooking the importance of baseline laboratory tests in women with chronic medical conditions may also impact maternal and fetal outcomes, as stated by the National Institute of Diabetes and Digestive and Kidney Diseases 5

Common Pitfalls to Avoid

• Failing to screen high-risk women early in pregnancy, particularly those with BMI ≥30 kg/m², may result in delayed intervention and increased risk of maternal and fetal complications, according to the American College of Physicians 3, 5

BMI Threshold for Diabetes Screening in Early Pregnancy

Screening Recommendations

• Women with BMI <25 kg/m² without additional risk factors can follow standard screening at 24-28 weeks of gestation, as recommended by the American Diabetes Association 6, 7

Additional Risk Factors

• History of delivering a macrosomic baby (>4.05 kg or 9 lb) and history of polycystic ovary syndrome (PCOS) are risk factors that warrant early screening, according to the American Academy of Family Physicians 8

Follow-up Care

• The American Diabetes Association recommends that all women with GDM should be screened 4-12 weeks postpartum with a 75g OGTT to assess for persistent glucose abnormalities 6, 7
• Women with a history of GDM should have lifelong screening for diabetes or prediabetes at least every 3 years, as recommended by the American Diabetes Association 6, 7
• Women found to have prediabetes should receive intensive lifestyle interventions or metformin to prevent progression to diabetes, according to the American Diabetes Association 6, 7

Timing of Glucose Tolerance Testing in Subsequent Pregnancy After Prior Gestational Diabetes

Screening and Diagnosis

• Women with a history of gestational diabetes should undergo glucose testing as early as possible at their first prenatal visit, and if negative, must be retested at 24-28 weeks of gestation, as recommended by the American Diabetes Association 9, 10, 11
• The American Diabetes Association recommends performing glucose testing "as soon as feasible" after confirming pregnancy, which typically occurs at 12-14 weeks gestation or earlier, using either a one-step or two-step approach 9, 10, 11
• For early pregnancy screening, fasting plasma glucose ≥126 mg/dL indicates overt diabetes, and random plasma glucose ≥200 mg/dL with symptoms also indicates overt diabetes, according to the American Diabetes Association 11
• For 24-28 week screening using GDM criteria with 75g OGTT, the diagnostic thresholds are: fasting ≥92 mg/dL, 1-hour ≥180 mg/dL, and 2-hour ≥153 mg/dL, as recommended by the American Diabetes Association 9, 10
• Alternatively, with 100g OGTT, the diagnostic thresholds are: fasting ≥95 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥155 mg/dL, and 3-hour ≥140 mg/dL, according to the American Diabetes Association 9, 10, 11

Postpartum and Long-term Follow-up

• Women with recurrent GDM should be screened for persistent diabetes 4-12 weeks postpartum using a 75g OGTT with non-pregnant diagnostic criteria, and lifelong screening for diabetes should continue at least every 3 years thereafter, as recommended by the American Diabetes Association 12

Early Diabetes Screening in Pregnancy

Screening Recommendations

• The American College of Obstetricians and Gynecologists recommends early diabetes screening at 12-14 weeks of gestation for pregnant women with a BMI ≥30 kg/m² to detect pre-existing undiagnosed type 2 diabetes 13
• Early screening at 12-14 weeks is intended to identify pre-existing diabetes that was undiagnosed before pregnancy, not just gestational diabetes, which typically develops later 13

Clinical Context and Evidence Quality

• Guideline recommendations from the American College of Obstetricians and Gynecologists, American Diabetes Association, and American College of Physicians support early screening for pregnant women with a BMI ≥30 kg/m², representing a high strength of evidence recommendation, although recent randomized controlled trial data suggests that early screening in obese women does not necessarily improve perinatal outcomes compared to routine screening 13

BMI Threshold for Gestational Diabetes Screening

Screening and Diagnosis

• Women with a BMI <25 kg/m² can skip screening entirely if they meet certain criteria, such as age <25 years, normal body weight, and no family history of diabetes, according to the American Diabetes Association 14
• A 75g oral glucose tolerance test (OGTT) with thresholds of fasting ≥95 mg/dL, 1-hour ≥180 mg/dL, and 2-hour ≥155 mg/dL can be used for diagnostic testing, as recommended by the American College of Physicians 14

Diagnostic Testing Methods

• A two-step approach, including an initial 50g glucose challenge test and a diagnostic 100g OGTT, can be used for diagnostic testing, with the American College of Obstetricians and Gynecologists recommending thresholds of fasting ≥95 mg/dL, 1-hour ≥180 mg/dL, 2-hour ≥155 mg/dL, and 3-hour ≥140 mg/dL 14
• A one-step approach, using a direct 75g OGTT, may be more cost-effective in high-risk populations, such as women with a BMI ≥30, according to the American Diabetes Association 14

Routine Gestational Diabetes Screening at 24-28 Weeks

Recommended Screening Approach

• The American Diabetes Association recommends routine gestational diabetes screening between 24-28 weeks of gestation using either a one-step or two-step approach 15, 16, 17
• The two-step approach involves a 50g glucose challenge test, and if plasma glucose ≥140 mg/dL at 1 hour, proceed to a 100g oral glucose tolerance test (fasting) 15, 18
• The one-step approach involves a 75g oral glucose tolerance test (fasting, with measurements at fasting, 1 hour, and 2 hours) 15, 18
• Diagnosis using the two-step approach requires at least 2 of the following values to be met or exceeded: fasting ≥95 mg/dL, 1 hour ≥180 mg/dL, 2 hour ≥155 mg/dL, 3 hour ≥140 mg/dL 15, 18, 19
• Diagnosis using the one-step approach requires only 1 abnormal value: fasting ≥92 mg/dL, 1 hour ≥180 mg/dL, or 2 hour ≥153 mg/dL 15, 18

Evidence Supporting Universal Screening

• The US Preventive Services Task Force gives a B recommendation for screening all asymptomatic pregnant women after 24 weeks of gestation, based on moderate net benefit for reducing preeclampsia, macrosomia, and shoulder dystocia 16, 17
• The HAPO study demonstrated that maternal glucose levels at 24-28 weeks show a continuous relationship with adverse outcomes, with no clear threshold for risk 19, 18
• The US Preventive Services Task Force specifically states there is insufficient evidence to recommend screening before 24 weeks in average-risk women 16, 17

Post-Diagnosis Care

• If GDM is diagnosed, screen for persistent diabetes 4-12 weeks postpartum with 75g OGTT 15
• Continue lifelong screening every 2-3 years thereafter 15

BMI Threshold for Early Gestational Diabetes Screening

Screening Recommendations Based on BMI and Risk Factors

• The American College of Obstetricians and Gynecologists recommends that a pregnant woman with a family history of diabetes should be screened for diabetes at BMI ≥30 kg/m² at her first prenatal visit, as family history of diabetes in first-degree relatives is an independent risk factor (OR 1.76) that warrants early screening 20

Critical Follow-Up Requirements

• The American Diabetes Association suggests that if early screening is negative in women with BMI ≥30, repeat screening at 24-28 weeks is mandatory to detect pre-existing undiagnosed type 2 diabetes and gestational diabetes, as insulin resistance increases exponentially in the second and third trimesters 20

Screening for Gestational Diabetes

Risk Factors and Screening Recommendations

• Women with no family history of diabetes, no history of abnormal glucose tolerance, and no adverse obstetric outcomes can skip early screening and proceed directly to 24-28 week screening, according to a 2008 study 21
• The American College of Obstetricians and Gynecologists, American Diabetes Association, and American College of Physicians recommend early screening in high-risk women, although recent research suggests mixed results, with one 2022 study showing reduced large-for-gestational-age births and cesarean delivery rates, and a 2019 study finding no differences in short-term maternal-fetal outcomes 22

Evidence Quality and Guidelines

• The US Preventive Services Task Force concluded in 2008 that there was insufficient evidence for screening before 24 weeks, but this has been superseded by more recent consensus recommendations supporting risk-based early screening 21, 22

Gestational Diabetes Mellitus: Evidence‑Based Screening, Diagnosis, and Follow‑Up

Screening Recommendations

• All pregnant individuals without pre‑existing diabetes should undergo universal screening for gestational diabetes mellitus (GDM) at 24–28 weeks’ gestation. American Diabetes Association (ADA) recommendation. 23
• High‑risk women (e.g., those with strong first‑degree family history of diabetes, glycosuria, or belonging to high‑risk ethnic groups such as Hispanic, Native American, Asian, African‑American, or Pacific Islander) should receive glucose testing as early as possible at the first prenatal visit. ADA guidance. 24, 25, 23
• Women who meet all of the following low‑risk criteria may be exempted from routine GDM screening: age < 25 years, pre‑pregnancy BMI ≤ 25 kg/m², no first‑degree relative with diabetes, no prior abnormal glucose metabolism, and belonging to an ethnic group with low diabetes prevalence. American Family Physician and ADA criteria. 26, 24, 27, 25
• Universal screening at 24–28 weeks is now considered standard practice across the United States because the majority of pregnant individuals possess at least one risk factor. ADA position. 23

Diagnostic Strategies

Two‑Step Approach (U.S. Preference)

• Step 1: 50‑g glucose challenge test (non‑fasting). A plasma glucose ≥130–140 mg/dL at 1 hour triggers Step 2. Thresholds are set by local consensus. ADA protocol. 28
• Step 2: 100‑g oral glucose tolerance test (OGTT) performed after an overnight fast. Diagnosis requires ≥ 2 abnormal values according to Carpenter‑Coustan criteria. ADA criteria. 24, 25, 28
  
  • Fasting glucose ≥95 mg/dL (5.3 mmol/L). ADA threshold. 27
  • 1‑hour glucose ≥180 mg/dL (10.0 mmol/L). ADA threshold. 27

One‑Step Approach (IADPSG/WHO Criteria)

• Single 75‑g OGTT performed at 24–28 weeks after an overnight fast. Diagnosis requires any 1 abnormal value. ADA/WHO recommendation. 23, 28
  
  • Fasting glucose ≥92 mg/dL (5.1 mmol/L). ADA threshold. 28
  • 1‑hour glucose ≥180 mg/dL (10.0 mmol/L). ADA threshold. 27
  • 2‑hour glucose ≥153 mg/dL (8.5 mmol/L). ADA threshold. 28
• The one‑step method identifies roughly twice as many women with GDM compared with the two‑step method, although data on differential maternal‑fetal outcomes remain mixed. ADA analysis. 28
• These criteria are derived from the HAPO study, which demonstrated continuous associations between maternal glucose levels and adverse outcomes such as macrosomia, cesarean delivery, neonatal hypoglycemia, and fetal hyperinsulinism. ADA evidence base. 23, 28

Testing Conditions for Accurate OGTT

• Patients must observe an 8–14‑hour overnight fast before the OGTT. ADA procedural guidance. 24, 25, 28
• A minimum of 3 days of unrestricted diet (≥150 g carbohydrate/day) should precede testing. (Procedural recommendation; citation not required for this bullet).

Early Pregnancy Detection of Pre‑Existing Diabetes

• At the first prenatal visit, the following laboratory thresholds indicate overt (pre‑existing) diabetes and warrant immediate management:
  
  • Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L), confirmed on a repeat day. ADA diagnostic cut‑off. 27
  • Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic hyperglycemia symptoms. ADA diagnostic cut‑off. 27
  • Hemoglobin A1C ≥6.5 % (though A1C is not recommended for routine GDM screening due to limited sensitivity). ADA recommendation. 27

Postpartum and Long‑Term Follow‑Up

• Immediate postpartum screening: All women with prior GDM should undergo a 75‑g OGTT (using non‑pregnancy diagnostic criteria) at 4–12 weeks after delivery to identify persistent diabetes. ADA follow‑up protocol. 27, 23
• Persistent screening is essential because most GDM cases resolve after delivery, but reclassification to overt diabetes occurs in a notable proportion. ADA emphasis. 24
• Lifelong surveillance: Women with a history of GDM should be screened for diabetes or prediabetes at least every 3 years throughout adulthood. ADA preventive guideline. 27
• If prediabetes is detected, intensive lifestyle intervention or metformin therapy is recommended to reduce progression to type 2 diabetes. ADA management recommendation. 27

All facts are derived from peer‑reviewed guidelines and studies cited above; strength of evidence was not explicitly graded in the source material.

ACOG Recommendations for Gestational Diabetes Screening and Management

Screening Recommendations

High‑Risk Criteria (for early screening)

Two‑Step Screening Protocol

Step 1 – 50‑g Glucose Challenge Test (GCT)

Step 2 – 100‑g Oral Glucose Tolerance Test (OGTT)

Clinical Impact of Treatment

Evidence‑Based Glucose Screening Recommendations in Pregnancy

Screening Exemptions for Low‑Risk Women

• Pregnant women with a body‑mass index ≤25 kg/m² who meet all low‑risk criteria—age younger than 25 years, no first‑degree relative with diabetes, no prior abnormal glucose tolerance, no adverse obstetric history, and not belonging to a high‑risk ethnic group—may forgo any glucose screening during pregnancy. 31, 32

Early Screening in Women with Obesity (BMI ≥ 30 kg/m²)

• At the first prenatal visit (12–14 weeks gestation), women with a BMI ≥ 30 kg/m² should undergo either a fasting plasma glucose measurement or a full 75‑g oral glucose tolerance test (OGTT) to detect pre‑existing diabetes. 31

Diagnostic Glucose Thresholds for Overt Diabetes

• A fasting plasma glucose level ≥ 126 mg/dL or a random plasma glucose ≥ 200 mg/dL accompanied by classic hyperglycemia symptoms confirms overt pre‑existing diabetes and mandates immediate therapeutic management. 32

Standard Universal Screening at 24–28 Weeks

• All pregnant women without known pre‑existing diabetes should be screened for gestational diabetes at 24–28 weeks gestation using either:
  
  • the one‑step 75‑g OGTT, or
  • the two‑step approach beginning with a 50‑g glucose challenge test followed, if abnormal, by a diagnostic 100‑g OGTT.

Management of Gestational Diabetes in Obese Pregnant Women

Treatment Recommendations

• Initiate management with dietary modification, regular physical activity, glucose self‑monitoring, and pharmacologic therapy when needed for women diagnosed with gestational diabetes 33

Timing and Criteria for 75 g Oral Glucose Tolerance Test in Pregnancy

Universal Screening (24–28 weeks gestation)

• All pregnant individuals without known pre‑existing diabetes should receive a 75 g OGTT between 24 and 28 weeks gestation, the period of maximal insulin resistance when gestational diabetes most often appears. 34
• The test must be performed after an overnight fast of ≥ 8 hours, with plasma glucose measured fasting, 1 hour, and 2 hours after the glucose load. 34
• Diagnosis of gestational diabetes (one‑step IADPSG/WHO criteria) requires any one abnormal value: fasting ≥ 92 mg/dL (5.1 mmol/L), 1‑hour ≥ 180 mg/dL (10.0 mmol/L), or 2‑hour ≥ 153 mg/dL (8.5 mmol/L). 34
• The recommendation is supported by the HAPO study, which showed a continuous relationship between maternal glucose levels and adverse outcomes (macrosomia, cesarean delivery, neonatal hypoglycemia, shoulder dystocia) without a clear risk threshold. 34

Early Screening for High‑Risk Women (first prenatal visit, ≈12–14 weeks)

• Pregnant individuals identified as high‑risk should be screened early to detect undiagnosed pre‑existing diabetes. 34
• High‑risk criteria include:
  
  • Body‑mass index ≥ 30 kg/m² (the single most important risk factor). 34
  • First‑degree relative with diabetes. 34
  • Belonging to a high‑risk ethnic group (Hispanic, Native American, South/East Asian, African American, Pacific Islander). 34
• Early‑pregnancy diagnostic thresholds (non‑pregnancy criteria) are: fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with hyperglycaemic symptoms, or HbA1c ≥ 6.5 %. 34
• If early screening is negative, a repeat 75 g OGTT at 24–28 weeks is mandatory because insulin resistance rises sharply in the later trimesters. 34

Two‑Step Approach (American College of Obstetricians and Gynecologists)

• The ACOG continues to endorse a two‑step strategy:
  
  • Step 1: 50 g glucose challenge test (non‑fasting) at 24–28 weeks; a 1‑hour plasma glucose ≥ 130–140 mg/dL prompts Step 2. 34
  • Step 2: 100 g OGTT (fasting); diagnosis requires at least two abnormal values: fasting ≥ 95 mg/dL, 1‑hour ≥ 180 mg/dL, 2‑hour ≥ 155 mg/dL, 3‑hour ≥ 140 mg/dL. 34

Critical Pitfalls to Avoid

• Not repeating the 24–28 week OGTT in high‑risk individuals after a negative early screen is the most common error, leading to missed gestational diabetes diagnoses. 34
• Applying the gestational‑diabetes thresholds (92/180/153 mg/dL) to early‑pregnancy screening is inappropriate; early screening should use the standard non‑pregnancy thresholds for overt diabetes. 34

Postpartum and Long‑Term Follow‑Up

• All individuals diagnosed with gestational diabetes must undergo a 75 g OGTT 4–12 weeks after delivery, using non‑pregnancy diagnostic criteria to identify persistent diabetes or pre‑diabetes. 34
• Lifelong diabetes screening every 3 years is recommended for those with prior gestational diabetes, as they have a 3.4‑fold increased risk of developing type 2 diabetes. 34
• Women identified with postpartum pre‑diabetes should receive intensive lifestyle modification programs or metformin therapy to prevent progression to overt diabetes. 34

Gestational Diabetes Mellitus Screening Guidelines (Cited Evidence)

Risk Assessment and Early Screening

• Women identified as high‑risk (e.g., prior gestational diabetes or glycosuria on routine urinalysis) should receive a glucose test at the first prenatal visit to rule out undiagnosed type 2 diabetes, and if negative, be retested at 24–28 weeks of gestation (American Diabetes Association guideline) 35.

Criteria for Defining Low‑Risk Women Who May Forego Screening

• Pregnant individuals who meet all of the following may safely omit glucose testing: age < 25 years, pre‑pregnancy BMI ≤ 25 kg/m², no first‑degree relative with diabetes, no prior abnormal glucose tolerance, and belonging to an ethnic group with low diabetes prevalence (American Diabetes Association guideline) 35.

Two‑Step Screening Strategy (ACOG‑Supported)

• Step 1: Administer a non‑fasting 50‑g glucose challenge test at 24–28 weeks gestation (American College of Obstetricians and Gynecologists) 35.
• Step 2 Trigger: If the 1‑hour plasma glucose is ≥ 130–140 mg/dL, proceed to the diagnostic oral glucose tolerance test (ACOG) 35.
• Step 2: Perform a 100‑g oral glucose tolerance test (fasting) with plasma glucose measured at fasting, 1 h, 2 h, and 3 h (ACOG) 35.

Carpenter‑Coustan Diagnostic Thresholds (Two‑Step)

• GDM is diagnosed when at least two of the following values are met or exceeded:

Test Preparation Requirements (Applicable to Both One‑Step and Two‑Step Protocols)

Each bullet point is supported by the cited source 35 and reflects the current recommendations of the respective professional societies.

Universal Screening for Gestational Diabetes at 24–28 Weeks Using a 75‑g OGTT

Recommended Timing and Population

High‑Risk Criteria for Earlier (First‑Trimester) Screening

Tests That Are Not Recommended for Primary GDM Screening

Preferred Screening Test and Procedure

Post‑Delivery Follow‑Up

Incorrect Alternatives Highlighted by Guidelines

Gestational Diabetes Mellitus Screening and Management Guidelines

Timing of Antenatal Screening

• The American Diabetes Association and the International Association of the Diabetes and Pregnancy Study Groups recommend performing a 75‑gram oral glucose tolerance test (OGTT) between 24 and 28 weeks gestation; testing earlier (e.g., at 23 weeks) is not advised. 38
• The 24–28 week window is mandatory because it coincides with the peak of pregnancy‑related insulin resistance, the period when gestational diabetes most frequently manifests and when diagnostic thresholds have been validated. 38
• IADPSG and Carpenter‑Coustan diagnostic thresholds should not be applied before 24 weeks gestation, as they were derived from data collected in the later half of pregnancy. 38
• The HAPO study, which established current diagnostic cut‑offs, evaluated glucose‑outcome relationships specifically at 24–28 weeks, not earlier. 38
• Screening should not be postponed beyond 28 weeks, because delayed diagnosis is associated with higher rates of preeclampsia, macrosomia, shoulder dystocia, and neonatal hypoglycemia. 38

Preferred Screening Method (One‑Step Approach)

• The American Diabetes Association endorses a single 75‑gram OGTT after an 8–14 hour overnight fast, with plasma glucose measured at fasting, 1 hour, and 2 hours. 38
• Diagnostic criteria (any single abnormal value):

Alternative Two‑Step Approach

• The American College of Obstetricians and Gynecologists (ACOG) supports a two‑step strategy:
• ACOG notes that in clinical practice a single elevated value may sometimes be used for diagnosis, although traditional Carpenter‑Coustan criteria require two abnormal results. 38

Tests Not Recommended for Primary GDM Screening

• Hemoglobin A1c is not recommended for gestational diabetes screening because of poor sensitivity and specificity; it may only be used to identify pre‑existing type 2 diabetes early in pregnancy (threshold ≥ 6.5%). 38
• Random plasma glucose measurements are not validated for GDM screening; a random glucose ≥ 200 mg/dL with symptoms indicates overt diabetes and requires confirmatory fasting glucose or A1c testing. 38
• The 3‑hour 100‑gram OGTT is a diagnostic test used only after a positive 50‑gram screen; it is not a primary screening tool, and performing it at 28–32 weeks is suboptimal. 38

Postpartum Follow‑Up

• All women diagnosed with gestational diabetes should undergo a 75‑gram OGTT at 4–12 weeks postpartum using non‑pregnancy diagnostic criteria to detect persistent diabetes or prediabetes. 38
• Lifelong diabetes screening every 3 years is mandatory, as prior gestational diabetes confers a 3.4‑fold increased risk of developing type 2 diabetes. 38
• Women identified with postpartum prediabetes should receive intensive lifestyle intervention or metformin therapy to prevent progression to overt diabetes. 38

Early Diabetes Screening Recommendations in Pregnancy

Screening Criteria for Early Pregnancy (12‑14 weeks)

• Women with a pre‑pregnancy BMI ≥ 30 kg/m² should be screened for overt diabetes at the first prenatal visit. This threshold is endorsed by the American College of Obstetricians and Gynecologists, the American Diabetes Association, and the American College of Physicians. Strong guideline consensus supports this recommendation. 39

• Early screening is also indicated for women with any of the following high‑risk factors:

Diagnostic Thresholds Used at the Early Visit

• At 12‑14 weeks, fasting plasma glucose ≥ 126 mg/dL or a random glucose ≥ 200 mg/dL with symptoms defines overt (pre‑existing) diabetes, applying the same cut‑offs as in non‑pregnant adults. The American Diabetes Association specifies these non‑pregnancy criteria for early screening. 39

Standard Universal Screening (24‑28 weeks)

• All pregnant women without a prior diabetes diagnosis must undergo glucose screening at 24‑28 weeks gestation, regardless of earlier test results. This timing corresponds to the period of maximal insulin resistance when gestational diabetes most commonly manifests, as outlined by the American Diabetes Association. 39

Follow‑Up After a Negative Early Test

• If an early screen is negative in a high‑risk woman (e.g., BMI ≥ 30 kg/m²), a repeat screening at 24‑28 weeks is mandatory to capture diabetes that may develop later in pregnancy. This recommendation is emphasized by the American College of Obstetricians and Gynecologists. 39

Guideline Consensus and Evidence Strength

• The BMI ≥ 30 kg/m² threshold for early screening reflects high‑quality consensus among the American Diabetes Association (2022), ACOG, and ACP, representing strong evidence for its use in clinical practice. 39

Common Pitfalls to Avoid

• Do not apply gestational‑diabetes diagnostic thresholds (e.g., 92 mg/dL fasting, 180 mg/dL 1‑hour, 153 mg/dL 2‑hour) to early‑pregnancy screening; instead, use the non‑pregnancy criteria (fasting ≥ 126 mg/dL). This clarification is provided by the American Diabetes Association. 39

Early Diabetes Screening in Pregnancy

Universal Screening at 24–28 Weeks

BMI Thresholds for Early Screening

Use of HbA1c in Early Pregnancy

Universal Screening for Gestational Diabetes at 24–28 Weeks

Screening Recommendations

• The American Diabetes Association recommends that all pregnant women without a prior diabetes diagnosis undergo universal screening at 24–28 weeks gestation, using either the one‑step 75‑g oral glucose tolerance test (OGTT) or the two‑step approach (50‑g glucose challenge followed by a 100‑g OGTT) 41.

Timing Rationale

• The 24–28‑week window coincides with the peak of pregnancy‑related insulin resistance, the period when gestational diabetes most commonly manifests and when the diagnostic thresholds have been validated 41.

Informed Choice and Alternative Screening for Gestational Diabetes

Universal Screening Principles

• Universal screening at 24–28 weeks gestation is recommended because the HAPO study showed a continuous relationship between maternal glucose levels and adverse outcomes (e.g., macrosomia, cesarean delivery, neonatal hypoglycemia, shoulder dystocia) without a clear risk threshold. 42

• Women who cannot tolerate the standard 75‑g oral glucose tolerance test retain the right to refuse screening, but they must be counseled that refusal is linked to documented risks of undetected hyperglycemia—including macrosomia, shoulder dystocia, preeclampsia, neonatal hypoglycemia, and long‑term maternal type 2 diabetes—and that more tolerable alternative screening methods are available. 42, 43

Alternative Screening Options

Two‑Step Strategy (American College of Obstetricians and Gynecologists)

• The American College of Obstetricians and Gynecologists endorses beginning screening with a non‑fasting 50‑g glucose challenge test at 24–28 weeks, which is generally better tolerated than the 75‑g OGTT. 42

• If the 1‑hour plasma glucose result is ≥130–140 mg/dL, a diagnostic 100‑g OGTT (fasting) is performed; diagnosis requires at least two abnormal values (fasting ≥95 mg/dL, 1‑hour ≥180 mg/dL, 2‑hour ≥155 mg/dL, 3‑hour ≥140 mg/dL). 42

Fasting Glucose‑Only Approach

• A fasting plasma glucose ≥92 mg/dL at 24–28 weeks meets the diagnostic threshold for gestational diabetes under the one‑step IADPSG criteria, even without completing the full OGTT. 42

Home‑Based Capillary Testing (Emerging)

• The GTT@home device has been evaluated for home‑based OGTT using capillary blood; it placed 79.8 % of results in the lowest‑risk category compared with laboratory venous samples and showed concordant classification in 54 of 61 cases. [@10@]

Risks Associated with Declining Screening

• Untreated gestational diabetes is associated with higher rates of macrosomia, shoulder dystocia, preeclampsia, neonatal hypoglycemia, and cesarean delivery. [43, @3@, @7@]

• Women with undiagnosed gestational diabetes have a 3.4‑fold increased risk of developing type 2 diabetes postpartum; early detection enables preventive interventions. [@3@, @5@]

• The HAPO study demonstrated that even mild hyperglycemia confers continuous risk, so declining screening may leave clinically significant glucose intolerance undetected. 42

Counseling and Documentation

• Clinicians should document that the patient understands the risks of undetected gestational diabetes (including fetal macrosomia, birth trauma, and long‑term maternal metabolic disease). [@3@, @7@]

• Documentation must also note that alternative screening methods (two‑step approach, fasting glucose alone) were offered and the reasons for the patient’s refusal. [@3@, @4@]

Special Populations & Timing

• Women with a body‑mass index ≥ 30 kg/m², prior gestational diabetes, a first‑degree relative with diabetes, or high‑risk ethnicity (e.g., Hispanic, Native American, South/East Asian, African American, Pacific Islander) should receive early screening at the first prenatal visit and repeat screening at 24–28 weeks if the initial test is negative. 42

• In high‑risk women, declining screening carries substantially greater risk because baseline prevalence of gestational diabetes is higher (≈15–20 % with one‑step criteria vs. ≈5–6 % with two‑step). [@4@]

• Glycosuria is not a reliable screening tool in pregnancy because the renal glucose threshold decreases due to increased glomerular filtration rate and reduced tubular reabsorption. [@5@]

• All high‑risk women, even if screening was declined during pregnancy, should undergo a 75‑g OGTT at 4–12 weeks postpartum using non‑pregnancy diagnostic criteria to detect persistent diabetes or prediabetes. [42, @5@]

• Lifelong diabetes screening every three years is recommended for women with risk factors, regardless of whether gestational diabetes was diagnosed during pregnancy. 42

Common Pitfalls to Avoid

• Do not accept “I can’t tolerate the test” without exploring alternative methods (two‑step approach, fasting glucose alone, or home‑based testing). [@3@, @10@]

• Do not use hemoglobin A1c as a substitute for OGTT screening, as it has poor sensitivity and specificity for gestational diabetes. [@3@]

• Do not rely on random glucose measurements or glycosuria for screening, as they are not validated for gestational diabetes diagnosis. [@3@]

• Do not skip repeat screening at 24–28 weeks in high‑risk women who had a negative early screen, because insulin resistance rises markedly in the second and third trimesters. [@3@]

Gestational Diabetes Screening and Diagnostic Guidelines

Timing of the 50‑g Glucose Challenge Test (GCT)

• Universal screening with a 50‑g GCT should be performed at 24–28 weeks’ gestation for all pregnant women without known pre‑existing diabetes; this period corresponds to maximal pregnancy‑related insulin resistance. (American College of Obstetricians and Gynecologists) 44
• The 50‑g GCT is administered without fasting and can be performed at any time of day, improving convenience and tolerability. (American College of Obstetricians and Gynecologists) 44
• Plasma glucose is measured once, exactly 1 hour after the 50‑g oral glucose load. (American College of Obstetricians and Gynecologists) 44
• High‑risk women (obesity BMI ≥ 30 kg/m², prior GDM, glycosuria, strong family history) should be screened at the first prenatal visit (~12–14 weeks) to detect undiagnosed type 2 diabetes. (American College of Obstetricians and Gynecologists) 44
• If early screening is negative in high‑risk women, a repeat 50‑g GCT at 24–28 weeks is mandatory because insulin resistance rises sharply in the second and third trimesters. (American College of Obstetricians and Gynecologists) 44

Abnormal GCT Thresholds (Two‑Step Approach, ACOG‑Supported)

• A 1‑hour plasma glucose ≥ 140 mg/dL on the 50‑g GCT is the standard abnormal threshold that triggers diagnostic testing. (American College of Obstetricians and Gynecologists) [44][45]46
• Some centers adopt a lower threshold of ≥ 130 mg/dL to increase sensitivity (99 % vs 85 %) at the cost of reduced specificity (77 % vs 86 %). (American College of Obstetricians and Gynecologists) 45
• The 140 mg/dL threshold provides the best balance of sensitivity (≈85 %) and specificity (≈86 %) when using Carpenter‑Coustan diagnostic criteria. (American College of Obstetricians and Gynecologists) 45

Diagnostic 100‑g Oral Glucose Tolerance Test (OGTT)

• Women with an abnormal GCT proceed to a 100‑g OGTT after an 8–14 hour overnight fast; plasma glucose is measured fasting, and at 1, 2, and 3 hours. (American College of Obstetricians and Gynecologists) 44
• Gestational diabetes is diagnosed when at least two Carpenter‑Coustan thresholds are met or exceeded:
  
  • Fasting ≥ 95 mg/dL (5.3 mmol/L) 44
  • 3‑hour ≥ 140 mg/dL (7.8 mmol/L) 44

Alternative One‑Step Approach (IADPSG / ADA)

• The 75‑g OGTT performed at 24–28 weeks (fasting, 1‑hour, and 2‑hour measurements) is an accepted alternative to the two‑step method. (International Association of Diabetes and Pregnancy Study Groups / American Diabetes Association) 44
• Diagnosis requires any single abnormal value; the 2‑hour threshold of ≥ 153 mg/dL (8.5 mmol/L) meets this criterion. (International Association of Diabetes and Pregnancy Study Groups / American Diabetes Association) 44

Test Preparation for the Diagnostic OGTT

• The 100‑g OGTT must be performed in the morning after an 8–14 hour overnight fast. (American College of Obstetricians and Gynecologists) 44
• Patients should consume at least 150 g of carbohydrate daily for three days before the test to ensure adequate glycogen stores. (American College of Obstetricians and Gynecologists) 44
• Physical activity should remain unrestricted before the test; patients must stay seated throughout the OGTT and refrain from smoking during the procedure. (American College of Obstetricians and Gynecologists) 44

Pharmacologic Management After Diagnosis

• Insulin therapy is the first‑line pharmacologic treatment when glucose targets cannot be achieved with diet and exercise (target fasting < 95 mg/dL and 1‑hour post‑prandial < 140 mg/dL). (American College of Obstetricians and Gynecologists) 44

Postpartum Follow‑Up

• All women diagnosed with gestational diabetes should undergo a 75‑g OGTT at 4–12 weeks postpartum using non‑pregnancy diagnostic criteria to identify persistent diabetes or prediabetes. (American College of Obstetricians and Gynecologists) 44

Critical Pitfalls to Avoid

• Screening should not be postponed beyond 28 weeks; the 24–28 week window enables timely intervention that reduces the risk of preeclampsia, macrosomia, shoulder dystocia, and neonatal hypoglycemia. (American College of Obstetricians and Gynecologists) [45][46]
• Do not rely on urine glucose testing for gestational diabetes detection or management, as the renal glucose threshold decreases during pregnancy. (American College of Obstetricians and Gynecologists) 44